Predicting <i>in vivo</i> cardiovascular properties of β‐blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responsesJillian G. Baker, Sheila M. Gardiner, Stephen J. Hill et al.|The FASEB Journal|2011Cited by 25
Synthesis and in Vitro and in Vivo Characterization of Highly β<sub>1</sub>-Selective β-Adrenoceptor Partial AgonistsShailesh N. Mistry, Barrie Kellam, Sheila M. Gardiner et al.|Journal of Medicinal Chemistry|2013Cited by 24
Novel selective β <sub>1</sub> ‐adrenoceptor antagonists for concomitant cardiovascular and respiratory diseaseJillian G. Baker, Peter M. Fischer, Sheila M. Gardiner et al.|The FASEB Journal|2017Cited by 20
Using Esterase Selectivity to Determine the <i>In Vivo</i> Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-BlockersJillian G. Baker, Peter M. Fischer, Christophe Fromont et al.|ACS Pharmacology & Translational Science|2020Cited by 4
In vitro and in vivo analysis of a novel highly selective β1-adrenoceptor partial agonist.Jillian G. Baker, Barrie Kellam, Stephen J. Hill et al.|Repository@Nottingham (University of Nottingham)|2012Cited by 0